Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 20 Jun 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2013 New source identified and integrated (Vanderbilt-Ingram Cancer Center record: VICCMEL1263).